Radiofrequency Ablation of Pulmonary Malignancy
- Determine the safety and toxicity of radiofrequency ablation in patients with
refractory or advanced pulmonary malignancies.
- Determine the efficacy of this treatment, in terms of local control, in these patients.
- Determine whether CT scan is a reasonable imaging assessment tool for treatment
delivery and follow-up in these patients.
OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the
tumor over 2 hours.
Patients are followed at 1, 3, 6, and 12 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
- Diagnosis of a primary or secondary intrathoracic malignancy
- Any cell type or origin
- Involving the intrapulmonary, mediastinal, or pleural/chest wall
- Inoperable primary or metastatic cancer to the lung
- Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy,
- Single or multiple lesions that are non-contiguous with vital structures or organs
- Great vessels
- Less than 5 cm in largest dimension
- Accessible via percutaneous transthoracic route
- Coagulation profile normal
Type of Study:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Robert D. Suh, MD
Jonsson Comprehensive Cancer Center
United States: Federal Government
- Lung Cancer
- Malignant Mesothelioma
- Metastatic Cancer
- Thymoma and Thymic Carcinoma
- recurrent non-small cell lung cancer
- recurrent small cell lung cancer
- recurrent malignant mesothelioma
- recurrent thymoma and thymic carcinoma
- stage IIIB non-small cell lung cancer
- stage IV non-small cell lung cancer
- pulmonary carcinoid tumor
- lung metastases
- Lung Neoplasms
- Neoplasm Metastasis
- Neoplasms, Second Primary
|Jonsson Comprehensive Cancer Center, UCLA
||Los Angeles, California 90095-1781